UNIGENE LABORATORIES INC

UNIGENE LABORATORIES INC, listed under CIK 352747, operates within the Medicinal Chemicals & Botanical Products space traditionally tied to SIC codes focused on pharmaceutical and botanical extract preparation, supplying specialized botanical compounds, standardized extracts, and contract research to nutraceutical, therapeutic, and personal-care manufacturers seeking compliant active ingredients; its operations blend in-house formulation with toll-manufacturing partnerships tailored to clients that prioritize botanical sourcing, regulatory traceability, and natural alternatives to synthetic actives. The company’s offerings span allergen-free extracts and botanical blends that are positioned to meet growing demand from health-conscious brands, yet UNIGENE must navigate stringent FDA and state-level botanical regulations, evolving quality-control expectations, and supply-chain dependencies for rare botanicals—factors that amplify risks around compliance, product consistency, and cost volatility. The most recent public disclosure is a Form 10-Q filed in November 1999, underscoring the need for investors to stay current. View live SEC filings on Earnings Feed.

Source: Earnings Feed research · last updated 11/24/2025